Abstract 81P
Background
Limited infiltration and exhaustion of transferred T cells are key factors impeding the development of adoptive cell immunotherapy in solid tumors. Efficient infiltration of activated T cells into tumors plays an important role in the therapeutic effect of adoptive cell immunotherapy. A tumor-penetrating peptide iRGD modified T cells (SmarT cells) were established to promote tumor-specific lymphocyte infiltration and enhanced the antitumor efficacy of PD-1 blocking strategy.
Methods
Here we report the interim analysis results of an ongoing phase 1/2 dose-escalation clinical trial of SmarT plus PD-1 mAb in patients with previously treated solid cancers (ChiCTR2200061306). The primary objective was safety for the combination of SmarT cells, low dose radiation and PD-1 mAb; secondary objectives included efficacy and dose-finding of SmarT cells.
Results
We treated 10 patients with three SmarT doses: 1.0 × 109, 5.0 × 109 or 10 × 109 cells. The low dose radiation (1Gy) was carried out 24 hours before SmarT injection. Three patients experienced a grade 2 fever. Two patients experienced a grade anemia. No cytokine release syndrome (CRS) occurred. No grade 3 or higher treatment-related adverse events or deaths were reported. A total of three patients had stable disease (SD) and seven patients had a progressive disease (PD). The disease control rate (DCR) reached 30.0%. The median progressive free survival time (mPFS) was 71 days and the median overall survival time (mOS) was 201 days.
Conclusions
These initial results suggest that SmarT cells has promising efficacy with an acceptable safety profile in patients with heavily pretreated solid cancers.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The legal committee of Nanjing Drumtower Hospital.
Funding
The funds for Clinical Trials from the Affiliated Drum Tower Hospital, Medical School of Nanjing University (No. 2022-LCYJ-ZD-05, B.L.).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
251P - LDH isozyme as a prognostic factor for patients with metastatic clear cell renal cell carcinoma (mCRCC)
Presenter: Hayato Takeda
Session: Poster Display
Resources:
Abstract
252P - Risk factors for recurrence after curative nephrectomy in non-metastatic renal cell carcinoma: A retrospective cohort study
Presenter: Kristine Tejada
Session: Poster Display
Resources:
Abstract
253TiP - WUTSUP-02-II-Neo-Dis-Tis: Investigating the efficacy and safety of neoadjuvant tislelizumab plus disitamab vedotin with adjuvant tislelizumab in upper urinary tract carcinoma: A phase II multi-center study
Presenter: Yige Bao
Session: Poster Display
Resources:
Abstract
254TiP - Prospective observational trial of cabozantinib plus nivolumab in Japanese patients with advanced or metastatic renal cell carcinoma: JACUMET trial
Presenter: Yuji Miura
Session: Poster Display
Resources:
Abstract
264P - Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy in patients with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Chia-Chi Lin
Session: Poster Display
Resources:
Abstract
266P - Clinical application and potential impact of liquid biopsy on the management of Chinese patients with metastatic castration-resistant prostate cancer (mCRPC): A territory-wide prospective analysis
Presenter: Wai Kay Philip Kwong
Session: Poster Display
Resources:
Abstract
267P - Exploring homologous recombination deficiency threshold for predicting response to PARP inhibitor in prostate cancer
Presenter: Diwei Zhao
Session: Poster Display
Resources:
Abstract
268P - Comparisons of on new-onset prostate cancer in type 2 diabetes mellitus exposed to the SGLT2I and DPP4I: A population-based cohort study
Presenter: Hou In Chou
Session: Poster Display
Resources:
Abstract
269P - Prostate cancer harboring low COMT expression correlates with a poor prognosis and response to enzalutamide
Presenter: Shigekatsu Maekawa
Session: Poster Display
Resources:
Abstract
270P - Germline BRCA1/2 pathogenic variants in Japanese patients with prostate cancer are predictive factors for androgen receptor-axis-targeted therapy or chemotherapy for castration-resistant prostate cancer
Presenter: Shigekatsu Maekawa
Session: Poster Display
Resources:
Abstract